Navigation Links
Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 11, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will present preclinical data for Talvesta(tm) (talotrexin) for Injection at the American Association for Cancer Research 100th Annual Meeting April 14-18, 2007 in Los Angeles, California.

Abstract No. 2210: "Combining talotrexin (PT-523) with paclitaxel in A549 non-small cell lung cancer (NSCLC) athymic nude mice xenografts" will be presented in a poster session on Monday, April 16, 2007 from 8:00am to 12:00pm PDT, in Poster Section 23, Tumor Biology 15, in the Exhibit Hall. Board No. 8.

About Talvesta(tm) (talotrexin) for Injection

Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talvesta has demonstrated enhanced antitumor activity in a broad spectrum of preclinical studies by targeting the enzyme DHFR to prevent DNA synthesis in tumor cells and inhibit tumor growth. These studies suggest that Talvesta, as compared to methotrexate, enters into cells up to ten times more efficiently and demonstrates 10- to 100-fold more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR, which Hana believes may further inhibit tumor growth. In May 2006, the U.S. Food and Drug Administration granted orphan drug designation for Talvesta in patients with ALL.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner o f choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at

The Hana Biosciences, Inc. logo is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to Talvesta or its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

-0- CONTACT: Hana Biosciences, Inc. Invest or & Media Contact: Remy Bernarda, Director, Investor Relations (650) 228-2769


Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
3. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/30/2015)... Elbit Imaging Ltd. (TASE, NASDAQ: ... that it was informed by InSightec Ltd. ("InSightec"), that the ... approved its Exablate Neuro system to treat movement, pain ... --> Insightec,s Exablate Neuro platform is transforming medicine ... technologies: Focused Ultrasound, which is used to lesion the ...
(Date:11/29/2015)... 29, 2015   Royal Philips  (NYSE: PHG, AEX: ... at the 2015 Radiological Society of North America Annual ... Place in Chicago . Visitors to ... company,s broad portfolio of integrated Diagnostic Imaging, Clinical Informatics, ... clinical performance, improve workflow and create a superior patient ...
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO Medical ... technology at the Radiological Society of ... Chicago November 29 – December ... designed to offer customers unrivaled versatility, enhanced user ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will ... close friend, or animal pass away, death lives among us. It is your perspective, ... from a family of 11 children, author T Sky understands that she may see ...
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont Systems, a ... Universal Integrator (VUI) extension unites with Syncro Soft’s latest software update, oXygen XML ... continuous process with the latest release of oXygen® XML editor and the Vasont® ...
(Date:11/30/2015)... ... 2015 , ... GKhair & Tibolli team members and artists were excited and ... November 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. ... top of the line fashion journalists. The San Juan Beauty Show carries immense credibility ...
(Date:11/30/2015)... CHICAGO, IL November 30, 2015 (PRWEB) , ... ... ... SpeechCheck and Winscribe are pleased to announce their strategic partnership at ... speech recognition consultants, SpeechCheck, Inc., and Winscribe, global providers of cutting-edge dictation ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI Group ... which empower organizations through communication analytics, announced today that their Proteus® VoIP QMS ... their service quality. , Proteus® VoIP QMS (Quality Management System) does ...
Breaking Medicine News(10 mins):